Interleukin-2 therapy in patients with HIV infection

D. Abrams, Y. Lévy, M. H. Losso, A. Babiker, G. Collins, D. A. Cooper, J. Darbyshire, S. Emery, L. Fox, F. Gordin, H. C. Lane, J. D. Lundgren, R. Mitsuyasu, J. D. Neaton, A. Phillips, J. P. Routy, G. Tambussi, D. Wentworth

Research output: Contribution to journalArticle

275 Citations (Scopus)

Abstract

BACKGROUND: Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increases is not known. METHODS: We conducted two trials: the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) study and the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT). In each, patients infected with the human immunodeficiency virus (HIV) who had CD4+ cell counts of either 50 to 299 per cubic millimeter (SILCAAT) or 300 or more per cubic millimeter (ESPRIT) were randomly assigned to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone. The interleukin-2 regimen consisted of cycles of 5 consecutive days each, administered at 8-week intervals. The SILCAAT study involved six cycles and a dose of 4.5 million IU of interleukin-2 twice daily; ESPRIT involved three cycles and a dose of 7.5 million IU twice daily. Additional cycles were recommended to maintain the CD4+ cell count above predefined target levels. The primary end point of both studies was opportunistic disease or death from any cause. RESULTS: In the SILCAAT study, 1695 patients (849 receiving interleukin-2 plus antiretroviral therapy and 846 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 202 cells per cubic millimeter were enrolled; in ESPRIT, 4111 patients (2071 receiving interleukin-2 plus antiretroviral therapy and 2040 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 457 cells per cubic millimeter were enrolled. Over a median follow-up period of 7 to 8 years, the CD4+ cell count was higher in the interleukin-2 group than in the group receiving antiretroviral therapy alone - by 53 and 159 cells per cubic millimeter, on average, in the SILCAAT study and ESPRIT, respectively. Hazard ratios for opportunistic disease or death from any cause with interleukin-2 plus antiretroviral therapy (vs. antiretroviral therapy alone) were 0.91 (95% confidence interval [CI], 0.70 to 1.18; P=0.47) in the SILCAAT study and 0.94 (95% CI, 0.75 to 1.16; P=0.55) in ESPRIT. The hazard ratios for death from any cause and for grade 4 clinical events were 1.06 (P=0.73) and 1.10 (P=0.35), respectively, in the SILCAAT study and 0.90 (P=0.42) and 1.23 (P=0.003), respectively, in ESPRIT. CONCLUSIONS: Despite a substantial and sustained increase in the CD4+ cell count, as compared with antiretroviral therapy alone, interleukin-2 plus antiretroviral therapy yielded no clinical benefit in either study. (ClinicalTrials.gov numbers, NCT00004978 [ESPRIT] and NCT00013611 [SILCAAT study].)

Original languageEnglish
Pages (from-to)1548-1559
Number of pages12
JournalNew England Journal of Medicine
Volume361
Issue number16
DOIs
Publication statusPublished - Oct 15 2009

Fingerprint

Virus Diseases
Interleukin-2
HIV
CD4 Lymphocyte Count
Therapeutics
Cause of Death
Confidence Intervals
aldesleukin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Abrams, D., Lévy, Y., Losso, M. H., Babiker, A., Collins, G., Cooper, D. A., ... Wentworth, D. (2009). Interleukin-2 therapy in patients with HIV infection. New England Journal of Medicine, 361(16), 1548-1559. https://doi.org/10.1056/NEJMoa0903175

Interleukin-2 therapy in patients with HIV infection. / Abrams, D.; Lévy, Y.; Losso, M. H.; Babiker, A.; Collins, G.; Cooper, D. A.; Darbyshire, J.; Emery, S.; Fox, L.; Gordin, F.; Lane, H. C.; Lundgren, J. D.; Mitsuyasu, R.; Neaton, J. D.; Phillips, A.; Routy, J. P.; Tambussi, G.; Wentworth, D.

In: New England Journal of Medicine, Vol. 361, No. 16, 15.10.2009, p. 1548-1559.

Research output: Contribution to journalArticle

Abrams, D, Lévy, Y, Losso, MH, Babiker, A, Collins, G, Cooper, DA, Darbyshire, J, Emery, S, Fox, L, Gordin, F, Lane, HC, Lundgren, JD, Mitsuyasu, R, Neaton, JD, Phillips, A, Routy, JP, Tambussi, G & Wentworth, D 2009, 'Interleukin-2 therapy in patients with HIV infection', New England Journal of Medicine, vol. 361, no. 16, pp. 1548-1559. https://doi.org/10.1056/NEJMoa0903175
Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA et al. Interleukin-2 therapy in patients with HIV infection. New England Journal of Medicine. 2009 Oct 15;361(16):1548-1559. https://doi.org/10.1056/NEJMoa0903175
Abrams, D. ; Lévy, Y. ; Losso, M. H. ; Babiker, A. ; Collins, G. ; Cooper, D. A. ; Darbyshire, J. ; Emery, S. ; Fox, L. ; Gordin, F. ; Lane, H. C. ; Lundgren, J. D. ; Mitsuyasu, R. ; Neaton, J. D. ; Phillips, A. ; Routy, J. P. ; Tambussi, G. ; Wentworth, D. / Interleukin-2 therapy in patients with HIV infection. In: New England Journal of Medicine. 2009 ; Vol. 361, No. 16. pp. 1548-1559.
@article{9145a9dddb6d4e9ea1de57a82cef9a6a,
title = "Interleukin-2 therapy in patients with HIV infection",
abstract = "BACKGROUND: Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increases is not known. METHODS: We conducted two trials: the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) study and the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT). In each, patients infected with the human immunodeficiency virus (HIV) who had CD4+ cell counts of either 50 to 299 per cubic millimeter (SILCAAT) or 300 or more per cubic millimeter (ESPRIT) were randomly assigned to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone. The interleukin-2 regimen consisted of cycles of 5 consecutive days each, administered at 8-week intervals. The SILCAAT study involved six cycles and a dose of 4.5 million IU of interleukin-2 twice daily; ESPRIT involved three cycles and a dose of 7.5 million IU twice daily. Additional cycles were recommended to maintain the CD4+ cell count above predefined target levels. The primary end point of both studies was opportunistic disease or death from any cause. RESULTS: In the SILCAAT study, 1695 patients (849 receiving interleukin-2 plus antiretroviral therapy and 846 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 202 cells per cubic millimeter were enrolled; in ESPRIT, 4111 patients (2071 receiving interleukin-2 plus antiretroviral therapy and 2040 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 457 cells per cubic millimeter were enrolled. Over a median follow-up period of 7 to 8 years, the CD4+ cell count was higher in the interleukin-2 group than in the group receiving antiretroviral therapy alone - by 53 and 159 cells per cubic millimeter, on average, in the SILCAAT study and ESPRIT, respectively. Hazard ratios for opportunistic disease or death from any cause with interleukin-2 plus antiretroviral therapy (vs. antiretroviral therapy alone) were 0.91 (95{\%} confidence interval [CI], 0.70 to 1.18; P=0.47) in the SILCAAT study and 0.94 (95{\%} CI, 0.75 to 1.16; P=0.55) in ESPRIT. The hazard ratios for death from any cause and for grade 4 clinical events were 1.06 (P=0.73) and 1.10 (P=0.35), respectively, in the SILCAAT study and 0.90 (P=0.42) and 1.23 (P=0.003), respectively, in ESPRIT. CONCLUSIONS: Despite a substantial and sustained increase in the CD4+ cell count, as compared with antiretroviral therapy alone, interleukin-2 plus antiretroviral therapy yielded no clinical benefit in either study. (ClinicalTrials.gov numbers, NCT00004978 [ESPRIT] and NCT00013611 [SILCAAT study].)",
author = "D. Abrams and Y. L{\'e}vy and Losso, {M. H.} and A. Babiker and G. Collins and Cooper, {D. A.} and J. Darbyshire and S. Emery and L. Fox and F. Gordin and Lane, {H. C.} and Lundgren, {J. D.} and R. Mitsuyasu and Neaton, {J. D.} and A. Phillips and Routy, {J. P.} and G. Tambussi and D. Wentworth",
year = "2009",
month = "10",
day = "15",
doi = "10.1056/NEJMoa0903175",
language = "English",
volume = "361",
pages = "1548--1559",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "16",

}

TY - JOUR

T1 - Interleukin-2 therapy in patients with HIV infection

AU - Abrams, D.

AU - Lévy, Y.

AU - Losso, M. H.

AU - Babiker, A.

AU - Collins, G.

AU - Cooper, D. A.

AU - Darbyshire, J.

AU - Emery, S.

AU - Fox, L.

AU - Gordin, F.

AU - Lane, H. C.

AU - Lundgren, J. D.

AU - Mitsuyasu, R.

AU - Neaton, J. D.

AU - Phillips, A.

AU - Routy, J. P.

AU - Tambussi, G.

AU - Wentworth, D.

PY - 2009/10/15

Y1 - 2009/10/15

N2 - BACKGROUND: Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increases is not known. METHODS: We conducted two trials: the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) study and the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT). In each, patients infected with the human immunodeficiency virus (HIV) who had CD4+ cell counts of either 50 to 299 per cubic millimeter (SILCAAT) or 300 or more per cubic millimeter (ESPRIT) were randomly assigned to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone. The interleukin-2 regimen consisted of cycles of 5 consecutive days each, administered at 8-week intervals. The SILCAAT study involved six cycles and a dose of 4.5 million IU of interleukin-2 twice daily; ESPRIT involved three cycles and a dose of 7.5 million IU twice daily. Additional cycles were recommended to maintain the CD4+ cell count above predefined target levels. The primary end point of both studies was opportunistic disease or death from any cause. RESULTS: In the SILCAAT study, 1695 patients (849 receiving interleukin-2 plus antiretroviral therapy and 846 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 202 cells per cubic millimeter were enrolled; in ESPRIT, 4111 patients (2071 receiving interleukin-2 plus antiretroviral therapy and 2040 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 457 cells per cubic millimeter were enrolled. Over a median follow-up period of 7 to 8 years, the CD4+ cell count was higher in the interleukin-2 group than in the group receiving antiretroviral therapy alone - by 53 and 159 cells per cubic millimeter, on average, in the SILCAAT study and ESPRIT, respectively. Hazard ratios for opportunistic disease or death from any cause with interleukin-2 plus antiretroviral therapy (vs. antiretroviral therapy alone) were 0.91 (95% confidence interval [CI], 0.70 to 1.18; P=0.47) in the SILCAAT study and 0.94 (95% CI, 0.75 to 1.16; P=0.55) in ESPRIT. The hazard ratios for death from any cause and for grade 4 clinical events were 1.06 (P=0.73) and 1.10 (P=0.35), respectively, in the SILCAAT study and 0.90 (P=0.42) and 1.23 (P=0.003), respectively, in ESPRIT. CONCLUSIONS: Despite a substantial and sustained increase in the CD4+ cell count, as compared with antiretroviral therapy alone, interleukin-2 plus antiretroviral therapy yielded no clinical benefit in either study. (ClinicalTrials.gov numbers, NCT00004978 [ESPRIT] and NCT00013611 [SILCAAT study].)

AB - BACKGROUND: Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increases is not known. METHODS: We conducted two trials: the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) study and the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT). In each, patients infected with the human immunodeficiency virus (HIV) who had CD4+ cell counts of either 50 to 299 per cubic millimeter (SILCAAT) or 300 or more per cubic millimeter (ESPRIT) were randomly assigned to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone. The interleukin-2 regimen consisted of cycles of 5 consecutive days each, administered at 8-week intervals. The SILCAAT study involved six cycles and a dose of 4.5 million IU of interleukin-2 twice daily; ESPRIT involved three cycles and a dose of 7.5 million IU twice daily. Additional cycles were recommended to maintain the CD4+ cell count above predefined target levels. The primary end point of both studies was opportunistic disease or death from any cause. RESULTS: In the SILCAAT study, 1695 patients (849 receiving interleukin-2 plus antiretroviral therapy and 846 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 202 cells per cubic millimeter were enrolled; in ESPRIT, 4111 patients (2071 receiving interleukin-2 plus antiretroviral therapy and 2040 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 457 cells per cubic millimeter were enrolled. Over a median follow-up period of 7 to 8 years, the CD4+ cell count was higher in the interleukin-2 group than in the group receiving antiretroviral therapy alone - by 53 and 159 cells per cubic millimeter, on average, in the SILCAAT study and ESPRIT, respectively. Hazard ratios for opportunistic disease or death from any cause with interleukin-2 plus antiretroviral therapy (vs. antiretroviral therapy alone) were 0.91 (95% confidence interval [CI], 0.70 to 1.18; P=0.47) in the SILCAAT study and 0.94 (95% CI, 0.75 to 1.16; P=0.55) in ESPRIT. The hazard ratios for death from any cause and for grade 4 clinical events were 1.06 (P=0.73) and 1.10 (P=0.35), respectively, in the SILCAAT study and 0.90 (P=0.42) and 1.23 (P=0.003), respectively, in ESPRIT. CONCLUSIONS: Despite a substantial and sustained increase in the CD4+ cell count, as compared with antiretroviral therapy alone, interleukin-2 plus antiretroviral therapy yielded no clinical benefit in either study. (ClinicalTrials.gov numbers, NCT00004978 [ESPRIT] and NCT00013611 [SILCAAT study].)

UR - http://www.scopus.com/inward/record.url?scp=70350441282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350441282&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa0903175

DO - 10.1056/NEJMoa0903175

M3 - Article

C2 - 19828532

AN - SCOPUS:70350441282

VL - 361

SP - 1548

EP - 1559

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 16

ER -